

2023

## 英文論文

1. 2023 **Kudo M**, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López López C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutrus CE, Lencioni R: Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. **J Hepatol** 78:133-141, 2023(IF=25.700).
2. 2023 Komeda Y, Kono M, Kashida H, Tribonias G, Masaki S, Takada R, Nagai T, Hagiwara S, Nishida N, Takenaka M, Honjo H, Matsui S, Tsuji N, **Kudo M**: Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: A case series. **Ann Gastroenterol** 36:97-102, 2023(IF=2.200).
3. 2023 Nishida N, **Kudo M**: Artificial intelligence models for the diagnosis and management of liver diseases. **Ultrasonography** 42:10-19, 2023(IF=3.100).
4. 2023 Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A: Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a

2023

## 英文論文

- large real life worldwide population. **Eur J Cancer** 180:9-20, 2023 (IF=8.400).
5. 2023 Takenaka M, Omoto S, Fukunaga T, **Kudo M**: The usefulness of texture and color-enhanced imaging for balloon endoscopy-assisted ERCP for hepatic-jejunal anastomotic stenosis. **Gastointest Endosc** 97:146-147, 2023(IF=7.700).
6. 2023 Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, **Kudo M**, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ: Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study. **Liver Int** 43:695-707, 2023 (IF=6.700).
7. 2023 Thabut D, **Kudo M**: Treatment of portal hypertension in patients with HCC at the era of Baveno VII. **J Hepatol** 78:658-662, 2023 (IF=25.700).
8. 2023 Aramaki O, Takayama T, Matsuyama Y, Kubo S, Kokudo N, Kuroasaki M, Murakami T, Shiina S, **Kudo M**, Sakamoto M, Nakashima O, Fukumoto T, Iijima H, Eguchi S, Soejima Y, Makuuchi M: Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: a Japanese nationwide survey. **Hepatol Res** 53:127-134, 2023 (IF=4.200).
9. 2023 Masuta Y, Minaga K, Kurimoto M, Sekai I, Hara A, Omaru N, Okai N, Otsuka Y, Takada R, Yoshikawa T, Masaki S, Kamata K, Honjo H, Arai Y, Yamashita K, **Kudo M**, Watanabe T: Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates toll-like receptor 9-mediated colonic inflammation through the induction of

2023

## 英文論文

- deubiquitinating enzyme A expression. **Int Immunol** 35:79-94, 2023 (IF=4.400).
10. 2023 **Kudo M\***: Prioritized requirements for first-line systemic therapy for hepatocellular carcinoma: Broad benefit with less toxicity. **Liver Cancer** 12:1-6, 2023. (IF=13.800)
11. 2023 Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed Y, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, **Kudo M**, Pinato D, Ang C: Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. **Front Oncol** 13:1128569, 2023. (IF=4.700)
12. 2023 Otsuka Y, Kamata K, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasound-guided puncture for the patients with pancreatic masses. **Diagnostics** 13:1039, 2023. doi: 10.3390/diagnostics13061039. (IF=3.600)
13. 2023 Otsuka Y, Komeda Y, Takeda M, Takahama T, Kono M, Takenaka M, Hagiwara S, Nishida N, Kashida H, **Kudo M**: Long-term survival of more than 5 years with maintenance therapy using single-agent pemetrexed in a patient with diffuse malignant peritoneal mesothelioma. **Case Rep Med** 2023:2092157, 2023. <https://doi.org/10.1155/2023/2092157> (IF=0.800)
14. 2023 Persano M, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Pressiani T, Piscaglia F, Kumada T, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A: Identification of Atezolizumab plus Bevacizumab prognostic index via recursive partitioning analysis in HCC: the ABE index. **Anticancer Res** 43:1599-1610, 2023. (IF=2.000)

2023

## 英文論文

15. 2023 Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, **Kudo M**, Tateishi R: Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines). **Hepatol Res** 53:383-390, 2023. (IF=4.200)
16. 2023 Kato N, **Kudo M**, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: final results of a multicenter phase 2 study. **Hepatol Res** 53:409-416, 2023. (IF=4.200)
17. 2023 Hagiwara S, Nishida N, **Kudo M**: Advances in immunotherapy for hepatocellular carcinoma. **Cancers** 15:2070, 2023. doi: 10.3390/cancers15072070 (IF=5.200)
18. 2023 Manabe T, Ogawa C, Kakuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Tani J, Shibatoge M, Morishita A, **Kudo M**, Masaki T: Usefulness of the measurement of psoas muscle volume for sarcopenia diagnosis in patients with liver disease. **Diagnostics** 13:1245, 2023. doi: 10.3390/diagnostics13071245 (IF=3.600)
19. 2023 Rimini M, Persano M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscablia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C,

2023

## 英文論文

- Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Corte AD, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Casinu S, Casadei-Gardini A: Real world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: How does adherence to the IMbrave150 trial inclusion criteria impact prognosis? **Targeted Oncol** 18:221-233, 2023. (IF=5.400)
20. 2023 Honjo H, Masuta Y, Otsuka Y, Masaki S, Minaga K, **Kudo M**, Watanabe T: Analyses of cytokine gene expression and fecal microbiota in a patient with Cronkhite-Canada syndrome successfully treated with prednisolone. **DEN Open** 4:e222, 2023. doi.org/10.1002/deo2.222 (IF=0.000)
21. 2023 Nishida N, Aoki T, Morita M, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, **Kudo M**: Non-inflamed tumor microenvironment and methylation/downregulation of antigen-presenting machineries in cholangiocarcinoma. **Cancers** 15:2379, 2023. doi: 10.3390/cancers15082379 (IF=5.200)
22. 2023 Morita M, Nishida N, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, **Kudo M**: Role of β-catenin activation in the tumor immune microenvironment and immunotherapy of hepatocellular carcinoma. **Cancers** 15:2311, 2023. doi: 10.3390/cancers15082311(IF=5.200)
23. 2023 Omoto S, Takenaka M, Fukunaga T, Takashima K, Komeda Y, Jeong S, **Kudo M**: The "echo-free space" technique: a safe and reliable method for endoscopic ultrasound scope insertion. **Endoscopy** 55:E698-E699, 2023. (IF=9.300)
24. 2023 **Kudo M\***: The Society for Immunotherapy of Cancer clinical

2023

## 英文論文

- practice guideline on immunotherapy for hepatocellular carcinoma. **Hepatobiliary Surg Nutr** 12:256-260,2023. (IF=8.000)
25. 2023 Kato H, Hagiwara S, Nishida N, Komeda Y, Yoshida A, **Kudo M**: A case of transcatheter arterial embolization for intraperitoneal hemorrhage due to gaint hepatic segmental arterial mediolysis. **Clin J Gastroenterol** 16:397-401, 2023. (IF=1.000)
26. 2023 Minami Y, Nishida N, **Kudo M**: Imaging diagnosis of various hepatocellular carcinoma subtypes and its hypervascular mimics: Differential diagnosis based on conventional interpretation and artificial intelligence. **Liver Cancer** 12:103-115, 2023. (IF=13.800)
27. 2023 **Kudo M\***: Surveillance, diagnosis, and treatment outcome of hepatocellular carcinoma in Japan: 2023 update. **Liver Cancer** 12:95-102, 2023. (IF=13.800)
28. 2023 Merle P†, **Kudo M†**, Krotneva S, Ozgurdal K, Su Y, Proskorovsky I: Regorafenib versus cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety. **Liver Cancer** 12:145-155, 2023 (†Shared 1st authors). (IF=13.800)
29. 2023 Kamata K, Hara A, Minaga K, Yoshikawa T, Kurimoto M, Sekai I, Okai N, Omaru N, Masuta Y, Otsuka Y, Takada R, Takamura S, **Kudo M**, Strober W, Watanabe T: Activation of the aryl hydrocarbon receptor inhibits the development of experimental autoimmune pancreatitis through IL-22-mediated signaling pathways. **Clin Exp Immunol** 212:171-183, 2023. (IF=4.600)
30. 2023 Persano M, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G,

2023

## 英文論文

Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Cascinu S, Casadei-Gardini A: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. **Oncology** 101:283-291, 2023. (IF=3.500)

31. 2023 Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, Yabushita K, Motoyoshi K, **Kudo M**: Safety and effectiveness of Lenvatinib in patients with unresectable hepatocellular carcinoma in real-world clinical practice: an observational post-marketing study in Japan. **Drugs-Real World Outc** 10:195-205, 2023. (IF=2.000)
32. 2023 Watanabe T, Minaga K, Honjo H, **Kudo M**: Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses. **Biochem Bioph Res Commun** 674:117-123, 2023. (IF=3.100)
33. 2023 Persano M, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Soldà C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G,

2023

## 英文論文

Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A.: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. **Eur J Cancer** 189:112933, 2023. doi: 10.1016/j.ejca.2023.05.021(IF=8.400)

34. 2023 **Kudo M\***: Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma. **Hepatobiliary Surg Nutr** 12:435-439,2023. (IF=8.000)
35. 2023 Singal AG, **Kudo M**, Bruix J: Breakthroughs in hepatocellular carcinoma therapies. **Clin Gastroenterol Hepatol** 21:2135-2149, 2023. (IF=12.600)
36. 2023 Masuta Y, Minaga K, Otsuka Y, Takenaka M, **Kudo M**: Usefulness of detective flow imaging endoscopic ultrasound for the diagnosis of rectal wall thickening. **Endosc Int Open** 11:E651-E652, 2023. (IF=2.600)
37. 2023 **Kudo M\***: Adjuvant atezolizumab-bevacizumab after resection or ablation for hepatocellular carcinoma. **Liver Cancer** 12:189-197,2023. (IF=13.800)
38. 2023 Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter

2023

## 英文論文

- M, Cortellini A, **Kudo M**, Rimassa L, Pinato DJ, Sharma R: Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. **Hepatol Int** 17:904-914, 2023. (IF=6.600)
39. 2023 Rimini M, Persano M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niieki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanakata T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tstsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini C: Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. **J Cancer Res Clin Oncol** 149:7565-7577, 2023. (IF=3.600)
40. 2023 Hirata D, Kashida H, Matsumoto T, Ebisutani C, Teramoto A, Iwatate M, Hattori S, Fujita M, Sano W, Komeda Y, Sano Y, Murakami Y, **Kudo M**: A multicenter prospective validation study on selective endoscopic resection of sessile serrated lesions using magnifying colonoscopy in clinical practice. **Digestion** 104:262-269, 2023. (IF=3.200)
41. 2023 Persano M, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG,

2023

## 英文論文

Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A.: Clinical outcomes with atezolizumab plus bevacizumab or Lenvatinib in patients with hepatocellular carcinoma: A multicenter real-world study. **J Cancer Res Clin Oncol** 149:5591-5602, 2023. (IF=3.600)

42. 2023 Kono M, Komeda Y, Tribonias G, Yoshida S, Nomura K, Handa K, Nagai T, Hagiwara S, Omoto S, Takenaka M, Nishida N, Tsuji N, Kashida H, **Kudo M**: Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naïve cases with ulcerative colitis. **JGH Open** 7:579-583, 2023.  
<https://doi.org/10.1002/jgh3.12953>. (IF=1.700)
43. 2023 Sangro B, Yau T, El-Khoueiry AB, **Kudo M**, Shen Y, Tschaika M, Roy A, Feng Y, Gao L, Urvi A: Exposure-response analysis for nivolumab plus Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). **Clin Transl Sci** 16:1445-1457, 2023. (IF=3.900)
44. 2023 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kaibori M, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kosaka H, Hiasa Y, **Kudo M**: Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients— multicenter

2023

## 英文論文

analysis. **Liver Cancer** 12:209-217, 2023. (IF=13.800)

45. 2023 **Kudo M\***, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki K, Jia J, Lencioni R: IMbrave 150: Efficacy and safety of atezolizumab plus bevacizumab vs sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the Phase III study. **Liver Cancer** 12:238-250, 2023. (IF=13.800)
46. 2023 Kawano K, Takenaka M, Kawano R, Katoh T, Nishi K, Kwon CI, **Kudo M**: Sliding tube-assisted ERCP in a patient who underwent double tract reconstruction anatomy after proximal gastrectomy. **Endoscopy** 55:E990-E992, 2023. (IF=9.300)
47. 2023 Masuta Y, Otsuka Y, Minaga K, Honjo H, **Kudo M**, Watanabe T: Regulation of type I IFN responses by deubiquitinating enzyme A in inflammatory bowel diseases. **J Clin Biochem Nutr** 73:103-107, 2023. (IF=2.400)
48. 2023 Otsuka Y, Minaga K, Hara A, Masuta Y, Takenaka M, **Kudo M**: Piercing technique for mucosal hyperplasia at an uncovered part of a partially covered stent after endoscopic ultrasound-guided hepaticogastrostomy. **Endosc Int Open** 11:E811-E813, 2023. (IF=2.600)
49. 2023 Omoto S, Takenaka M, Fukunaga T, Okamoto A, Komeda Y, Jeong S, **Kudo M**: Diagnosis of an intraductal papillary neoplasm of the bile duct with fibrovascular stalks using detective flow imaging. **Endoscopy** 55:E1012-E1014, 2023. (IF=9.300)
50. 2023 Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hanataka T, Kakizaki S, Shimada N, Kawata K,

2023

## 英文論文

- Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Comparison between atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma in patients with Child-Pugh class B in real-world clinical settings. **Oncology** 101:542-552, 2023. (IF=3.500)
51. 2023 Kamata K, Imai H, Matsumoto H, Yamashita Y, Kato T, Nishi K, Omoto S, Minaga K, Yamao K, Hyodo T, Im SW, Hara A, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Ueshima K, Chiba Y, Takenaka M, Watanabe T, Kitano M, **Kudo M**: Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial. **JGH Open** 7:659-666, 2023. (IF=1.700)
52. 2023 Iijima H, **Kudo M\***, Kubo S, Kurosaki M, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Fukumoto T, Matsuyama Y, Murakami T, Takahashi A, Miyata H, Kokudo N: Report of the 23rd nationwide follow-up survey of Primary Liver Cancer in Japan (2014–2015). **Hepatol Res** 53:895-959, 2023. (IF=4.200)
53. 2023 Minami Y, Aoki T, Hagiwara S, **Kudo M**: Tips for preparing and practicing thermal ablation therapy of hepatocellular carcinoma. **Cancers** 15:4763. doi: 10.3390/cancers15194763 (IF=5.200)
54. 2023 Vogel A, Kelley RK, Johnson P, Merle P, Yau T, **Kudo M**, Meyer T, Rimassa L: Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review. **Liver Cancer** 12:372-391, 2023. (IF=13.800)
55. 2023 Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X,

2023

## 英文論文

- Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, **Kudo M**, Yang JD, Pinato DJ, Ji F: Immune checkpoint inhibitors for Child-Pugh class B advanced hepatocellular carcinoma: A systematic review and meta-analysis. **JAMA Oncol** 9:1423-1431, 2023. (IF=28.400)
56. 2023 **Kudo M\***: All stages of hepatocellular carcinoma patients benefit from systemic therapy combined with locoregional therapy. **Liver Cancer** 12:395-404, 2023. (IF=13.800)
57. 2023 **Kudo M\***, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, Sakamoto N, Kato N, Nakano M, Jia J, Vogel A: Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the Phase III IMbrave150 study. **Liver Cancer** 12:479-493, 2023. (IF=13.800)
58. 2023 Merle P, **Kudo M**, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B, Breder V, Lim HY, Ogasawara S, Cattan S, Chao Y, Siegel AB, Martinez-Forero I, Wei Z, Liu C-C, Finn RS: Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: Longer-term follow-up from the Phase 3 KEYNOTE-240 trial. **Liver Cancer** 12:309-320, 2023. (IF=13.800)
59. 2023 **Kudo M\***: Drug-off criteria in patients with hepatocellular carcinoma who achieved clinical complete response after combination treatment with immunotherapy and locoregional therapy. **Liver Cancer** 12:289-296, 2023. (IF=13.800)
60. 2023 **Kudo M\***, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N:

2023

## 英文論文

Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter proof-of-concept study. **Liver Cancer** 12:321-338, 2023. (IF=13.800)

61. 2023 Kamata K, Takenaka M, Nishida N, Hara A, Otsuka Y, Tanaka H, Omoto S, Minaga K, Yamao K, Chiba Y, Sakai K, Nishio K, Watanabe T, **Kudo M**: Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. **Int J Clin Oncol** 28:1511-1519, 2023. (IF=3.300)
62. 2023 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, **Kudo M**: Does first-line treatment have prognostic impact for unresectable HCC? –Atezolizumab plus bevacizumab versus lenvatinib. **Cancer Med** 12:325-334, 2023. (IF=4.000)
63. 2023 Komatsu S, Ueshima K, Kido M, Kuramitsu K, Tsugawa D, Yanagimoto H, Toyama H, Ku E, **Kudo M**, Fukumoto T: Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: a bi-institutional propensity-matched cohort study. **J Hepato-Bil-Pan Sci** 30:303-314, 2023. (IF=3.000)
64. 2023 Fujita S, Honjo H, Takada R, Hara A, Masuta Y, Otsuka Y, Handa K, Minaga K, Tsuji S, **Kudo M**, Watanabe T: Ulcerative colitis-associated spondyloarthritis successfully treated with

2023

## 英文論文

- infliximab in the absence of enhanced TNF- $\alpha$  responses.  
**Intern Med** 62:2493-2497, 2023. (IF=1.200)
65. 2023 Takenaka M, Lee TH, **Kudo M**: Glove box method: Simple and effective right-hand free method for interventional endoscopy.  
**Dig Endosc** 35:e142-e143, 2023. (IF=5.300)
66. 2023 Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J, De Toni E, **Kudo M**, Eiblmaier A, Klein HG, Hegel JK, Madin K, Kroeniger K, Sharma A, Chan HLY: Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. **Hepatol Commun** 7:e0317, 2023. doi: 10.1097/HC9.0000000000000317 (IF=5.100)
67. 2023 Arizumi T, Minami T, Kono M, Chishina H, Takita M, Hagiwara S, Minami Y, Sakurai T, Ueshima K, Nishida N, **Kudo M\***: Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transarterial chemoembolization. **BioMedical Journal of Scientific & Technical Research (BJSTR)**, 2023. (IF=1.229)
68. 2023 Yoshida S, Minaga K, Watanabe T, **Kudo M**: Multiple pancreatic masses with rich vascularity. **J Gastroenterol Hepatol** 38: 10, 2023. doi: 10.1111/jgh.16060 (IF=4.100)
69. 2023 Qin S†, Chen M†, Cheng AL†, Kaseb AO†, **Kudo M†**, Lee HC†, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH, for the IMbrave050 investigators: Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. **Lancet** 402:1835-1847, 2023. (†Shard 1st authors) (IF=168.900)

2023

## 英文論文

70. 2023 Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A, Abrahamovych O, Afanasieva H, Aitova L, Altintas E, Altwegg R, Andreev P, Aomatsu K, Augustyn M, Balestrieri P, Begun J, Brunatto L, Bulgheroni D, Bunkova E, Cabello M, Cao Q, Caprioli F, Cerqueira R, Chen B, Chen CC, Chen CP, Chiu CT, Choi CH, Cicala M, Datsenko O, Dewint P, Domenech E, Dutré J, Duvall G, Fernandez J, Filip R, Fogel R, Fowler S, Fujii T, Fukata M, Furumoto Y, Gasbarrini A, Gawdis-Wojnarska B, Gilletta C, Gionchetti P, Goldin E, Golovchenko O, Gonciarz M, Gonen C, Segura GG, Gridnyev O, Gyokeres T, Hébuterne X, Hedin C, Hellström P, Hilmi IN, Horný I, Horvat G, Hoshi N, Hrdlicka L, Ishihara S, Ivanishyn O, Jang BI, Junior O, Kagaya T, Kanmura S, Karakina M, Katsuhiko N, Kierkus J, Kim HJ, Kim TO, Kim YH, Kiss GG, Klaus J, Kleczkowski D, Klopocka M, Kobayashi T, Kobielsz-Gembala I, Koo JS, Kopon A, Kravchenko T, **Kudo M**, Kwon KA, Lago P, Laharie D, Lawrance I, Leszczyszyn J, Li Y, Lukas M, Maaser C, Maemoto A, Marusawa H, McBride M, Mendu S, Miheller P, Miyabayashi H, Mohl W, Moore G, Motoya S, Murali N, Naem M, Nakajima K, Nakamoto Y, Nancey S, Neto J, Onizawa M, Ono Y, Ono Y, Osada T, Osipenko M, Owczarek D, Patel B, Patel K, Petrova E, Poroshina E, Portela F, Prystupa L, Rivero M, Roblin X, Romatowski J, Rydzewska G, Saibeni S, Sakuraba H, Samaan M, Schultz M, Schulze J, Sedghi S, Seidler U, Shin SJ, Stanislavchuk M, Stokesberry D, Suzuki T, Taguchi H, Tankova L, Thin L, Tkachev A, Torrealba L, Tsarynna N, Tulassay Z, Ueo T, Valuyskikh E, Vasilevskaya O, Viamonte M, Wei SC, Weisshof R, Wojcik K, Ye BD, Yen HH, Yoon H, Yoshida K, Yurkiv A, Zaha O, Zhan Q: Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR Phase 2b induction study. **Gastroenterology** 165:1443-1457, 2023. (IF=29.400)

2023

## 英文論文

71. 2023 **Kudo M\***: Current therapeutic strategies for hepatocellular carcinoma in Japan. **Liver Cancer** 12:497-509, 2023. (IF=13.800)
72. 2023 Vogel A, Finn RS, Blanchet Zumofen M, Heuser C, Sanchez Alvarez J, Leibfried M, Mitchell CR, Batson S, Redhead G, Gaillard V, **Kudo M**: Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular cancer in the first-line setting: systematic literature review and meta-analysis. **Liver Cancer** 12:510-520, 2023. (IF=13.800)
73. 2023 Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, **Kudo M**, D'Alessio A, Rimassa L, Pinato DJ, Ang C: Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. **World J Gastrointest Oncol** 15:1900-1912, 2023. (IF=3.000)
74. 2023 Llovet JM, **Kudo M**, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutkus C, Dubrovsky L, Siegel AB, Finn RS, for the LEAP-002 Investigators: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial. **Lancet Oncol** 24:1399-1410, 2023. (IF=51.100)
75. 2023 Otsuka Y, Hara A, Minaga K, Sekai I, Kurimoto M, Masuta Y, Takada R, Yoshikawa T, Kamata K, **Kudo M**, Watanabe T:

2023

## 英文論文

Leucine-rich repeat kinase 2 promotes the development of experimental severe acute pancreatitis. **Clin Exp Immunol** 214:182-196, 2023. (IF=4.600)

76. 2023 Abou-Alfa GK, Lau G, **Kudo M**, Chan SL, Kelly RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B, fro the HIMALAYA Investigators: Plain language summary of results from the HIMALAYA study: tremelimumab and durvalumab for the treatment of participants with unresectable hepatocellular carcinoma. **Future Oncol** 19:2505-2516, 2023. (†Shard 1st authors) (IF=3.300)
77. 2023 Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang TW, Knobloch G, Koh DM, **Kudo M**, Lee JM, Murakami T, Pinato D, Ringe KI, Song B, Tabrizian P, Wang J, Yoon JH, Zeng M, Zhou J, Vilgrain V: Consensus report from the 10th global forum for liver magnetic resonance imaging: developments in HCC management. **Eur Radiol** 33:9152-9166, 2023. (IF=5.900)
78. 2023 Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang TW, Knobloch G, Koh DM, **Kudo M**, Lee JM, Murakami T, Pinato D, Ringe KI, Song B, Tabrizian P, Wang J, Yoon JH, Zeng M, Zhou J, Vilgrain V: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. **Eur Radiol** 33:9167-9181, 2023. (IF=5.900)
79. 2023 Sugimori H, Masaki S, Honjo H, **Kudo M**, Watanabe T: Visualization of gastrointestinal bezoar movement causing and releasing small bowel obstruction on computed tomography in a patient with diabetes mellitus. **Cureus** 15:e49133. doi:

2023

## 英文論文

10.7759/cureus.49133 (IF=1.200)

80. 2023 Komeda Y, Tribonias G, Kono M, Handa K, Omoto S, Takenaka M, Hagiwara S, Tsuji N, Nishida N, Kashida H, **Kudo M**: Real-world data on short-term and long-term treatment results of ustekinumab in patients with steroid-resistant/dependent ulcerative colitis. **Inflamm Intest Dis** 8:161-166, 2023. (IF=0.000)
81. 2023 Qin S, **Kudo M**, Meyer T, Bai Y, Guo Y, Meng Z, Satoh T, Marino D, Assenat E, Li S, Chen Y, Boisserie F, Abdushaitov R, Finn RS, Vogel A, Zhu AX: Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A Phase 3 randomized clinical trial. **JAMA Oncol** 9:1651-1659, 2023. (IF=28.400)
82. 2023 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohma H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, **Kudo M**: Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma. **Liver Int** 44:113-124, 2023. (IF=6.700)
83. 2023 Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, **Kudo M**, Kumada T: Comparing the impact of

2023

## 英文論文

- atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach. **Cancer Med** 12:21680-21693, 2023. (IF=4.000)
84. 2023 Sim YK, Chong MC, Gandhi M, Pokharkar YM, Zhu Y, Shi L, Lequn L, Chen CH, **Kudo M**, Lee JH, Strasser SI, Chanwat R, Chow PKH: Real-world data on the diagnosis, treatment and management of hepatocellular carcinoma in the Asia-Pacific: The INSIGHT study. **Liver Cancer** 13:298-313, 2023. (IF=13.800)
85. 2023 Nishida N, **Kudo M**: Genetic/Epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: Transforming the immune microenvironment with molecular-targeted agents. **Liver Cancer** 13:136-149, 2023. (IF=13.800)
86. 2023 **Kudo M\***, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pachart M, Meyer T, Nagano S, Saito K, Mody K, Ramji Z, Dubrovsky L, Llovet JM: A Phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: Extended analysis of study 116. **Liver Cancer** 13:451-458, 2023 (IF=13.800)
87. 2023 **Kudo M\***, Tsuchiya K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M: Impact of bevacizumab being skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: An exploratory analysis of the Phase III IMbrave150 study. **Liver Cancer** 13:401-412, 2023. DOI: 10.1159/000535501 (IF=13.800)